Mantle cell lymphoma (MCL) is a chronically relapsing aggressive type of B-cell non-Hodgkin lymphoma considered incurable by currently used treatment approaches. Fludarabine is a purine analog clinically still widely used in the therapy of relapsed MCL. Molecular mechanisms of fludarabine resistance have not, however, been studied in the setting of MCL so far. We therefore derived fludarabine-resistant MCL cells (Mino/FR) and performed their detailed functional and proteomic characterization compared to the original fludarabine sensitive cells (Mino). We demonstrated that Mino/FR were highly cross-resistant to other antinucleosides (cytarabine, cladribine, gemcitabine) and to an inhibitor of Bruton tyrosine kinase (BTK) ibrutinib. Sensitivity to other types of anti-lymphoma agents was altered only mildly (methotrexate, doxorubicin, bortezomib) or remained unaffacted (cisplatin, bendamustine). The detailed proteomic analysis of Mino/FR compared to Mino cells unveiled over 300 differentially expressed proteins. Mino/FR were characterized by the marked downregulation of deoxycytidine kinase (dCK) and BTK (thus explaining the observed crossresistance to antinucleosides and ibrutinib), but also by the upregulation of several enzymes of de novo nucleotide synthesis, as well as the up-regulation of the numerous proteins of DNA repair and replication. The significant upregulation of the key antiapoptotic protein Bcl-2 in Mino/FR cells was associated with the markedly increased sensitivity of the fludarabine-resistant MCL cells to Bcl-2-specific inhibitor ABT199 compared to fludarabine-sensitive cells. Our data thus demonstrate that a detailed molecular analysis of drug-resistant tumor cells can indeed open a way to personalized therapy of resistant malignancies.

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Prague Czech Republic; 1st Department of Medicine Department of Hematology General University Hospital and Charles University Prague Prague Czech Republic

Institute of Pathological Physiology 1st Faculty of Medicine Charles University Prague Prague Czech Republic; Institute of Hematology and Blood Transfusion Prague Czech Republic

Thermo Fisher Scientific Bremen Germany

Zobrazit více v PubMed

Dreyling M, Kluin-Nelemans HC, Beà S, Klapper W, Vogt N, Delfau-Larue M-H, et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma. 2013; 54:699–707. 10.3109/10428194.2012.733882 PubMed DOI

Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012; 367:520–31. 10.1056/NEJMoa1200920 PubMed DOI

Jares P, Colomer D, Campo E: Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012; 122:3416–23. 10.1172/JCI61272 PubMed DOI PMC

Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064–71. PubMed

Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol. 2010;28:418–23. 10.1200/JCO.2009.24.1570 PubMed DOI PMC

Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002; 41:93–103. PubMed

de Campos-Nebel M, Larripa I, González-Cid M. Non-homologous end joining is the responsible pathway for the repair of fludarabine-induced DNA double strand breaks in mammalian cells. Mutat Res. 2008; 646:8–16. 10.1016/j.mrfmmm.2008.08.013 PubMed DOI

Månsson E, Spasokoukotskaja T, Sällström J, Eriksson S, Albertioni F. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res. 1999; 59:5956–63. PubMed

Månsson E, Flordal E, Liliemark J, Spasokoukotskaja T, Elford H, Lagercrantz S, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol. 2003; 65:237–47. PubMed

Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L, et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and-insensitive populations. Blood 2005; 105:767–74. PubMed

Reiman T, Graham KA, Wong J, Belch AR, Coupland R, Young J, et al. Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study. Leukemia. 2002;16:1886–87. PubMed

Moussay E, Palissot V, Vallar L, Poirel HA, Wenner T, El Khoury V, et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer 2010; 9:115 10.1186/1476-4598-9-115 PubMed DOI PMC

Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G, et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 2011; 118:3579–90. 10.1182/blood-2011-03-340364 PubMed DOI PMC

Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio M, Almasan A. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. Cell Death Dis. 2013; 4:e628 10.1038/cddis.2013.155 PubMed DOI PMC

de la Fuente MT, Casanova B, Cantero E, Hernández del Cerro M, Garcia-Marco J, Silva A, et al. Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine. Biochem Biophys Res Commun. 2003; 311:708–12. PubMed

Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114:2589–97. 10.1182/blood-2009-05-224071 PubMed DOI

Messina M, Del Giudice I, Khiabanian H, Rossi D, Chiaretti S, Rasi S, et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood 2014; 123:2378–88. 10.1182/blood-2013-10-534271 PubMed DOI PMC

Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012; 119:2854–62. 10.1182/blood-2011-12-395673 PubMed DOI

Sharma A, Janocha AJ, Hill BT, Smith MR, Erzurum SC, Almasan A. Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells. Mol Cancer Res. 2014; 12:1205–15. 10.1158/1541-7786.MCR-14-0124 PubMed DOI PMC

Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007; 25:5448–57. PubMed

Lai R, McDonnell TJ, O'Connor SL, Medeiros LJ, Oudat R, Keating M, et al. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res. 2002; 26:849–55. PubMed

Wiśniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods 2009; 6:359–62. 10.1038/nmeth.1322 PubMed DOI

Brosch M, Yu L, Hubbard T, Choudhary J. Accurate and sensitive peptide identification with Mascot Percolator. J Proteome Res. 2009; 8:3176–81. 10.1021/pr800982s PubMed DOI PMC

Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002; 1:376–86. PubMed

Arnér ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther. 1995; 67:155–86. PubMed

Bai L, Yamaguchi M, Tatsumi M, Kon K, Bräutigam M. Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-beta-D-arabinofuranosyl-2-fluoroadenine. J Cancer Res Clin Oncol. 1998; 124:367–73. PubMed

Lotfi K, Månsson E, Spasokoukotskaja T, Pettersson B, Liliemark J, Peterson C. et al. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res. 1999; 5:2438–44. PubMed

Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 2011; 6:e23372 10.1371/journal.pone.0023372 PubMed DOI PMC

Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, et al. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Mol Cancer 2014; 13:159 10.1186/1476-4598-13-159 PubMed DOI PMC

Natsumeda Y, Prajda N, Donohue JP, Glover JL, Weber G: Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues. Cancer Res. 1984; 44:2475–9. PubMed

Austin WR, Armijo AL, Campbell DO, Singh AS, Hsieh T, Nathanson D, et al. Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress. J Exp Med. 2012; 209:2215–28. 10.1084/jem.20121061 PubMed DOI PMC

Heale JT, Ball AR Jr, Schmiesing JA, Kim JS, Kong X, Zhou S, et al. Condensin I interacts with the PARP-1-XRCC1 complex and functions in DNA single-strand break repair. Mol Cell. 2006; 21:837–48. PubMed PMC

Li P, Jin H, Yu HG. Condensin suppresses recombination and regulates double-strand break processing at the repetitive ribosomal DNA array to ensure proper chromosome segregation during meiosis in budding yeast. Mol Biol Cell. 2014; 25:2934–47. 10.1091/mbc.E14-05-0957 PubMed DOI PMC

Constantinou A. Rescue of replication failure by Fanconi anaemia proteins. Chromosoma 2012; 121:21–36. 10.1007/s00412-011-0349-2 PubMed DOI PMC

Smith SC, Petrova AV, Madden MZ, Wang H, Pan Y, Warren MD, et al. A gemcitabine sensitivity screen identifies a role for NEK9 in the replication stress response. Nucleic Acids Res. 2014; 42:11517–27. 10.1093/nar/gku840 PubMed DOI PMC

Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609–19. PubMed

Reed JC. Balancing cell life and death: bax, apoptosis, and breast cancer. J Clin Invest. 1996; 97:2403–4. PubMed PMC

Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 1997; 34:9–19. PubMed

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19:202–8. 10.1038/nm.3048 PubMed DOI

Saba N, Wiestner A. Do mantle cell lymphomas have an 'Achilles heel'? Curr Opin Hematol. 2014; 21:350–7. 10.1097/MOH.0000000000000057 PubMed DOI PMC

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369:507–16. 10.1056/NEJMoa1306220 PubMed DOI PMC

Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000; 175:120–7. PubMed

Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013; 37:1271–7. 10.1016/j.leukres.2013.07.028 PubMed DOI

Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015. PubMed

Cyster JG, Goodnow CC. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity 1995; 2:13–24. PubMed

Vié N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, et al. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer 2008; 7:14 10.1186/1476-4598-7-14 PubMed DOI PMC

Florczyk U, Golda S, Zieba A, Cisowski J, Jozkowicz A, Dulak J. Overexpression of biliverdin reductase enhances resistance to chemotherapeutics. Cancer Lett. 2011; 300:40–7. 10.1016/j.canlet.2010.09.003 PubMed DOI

Kim SS, Seong S, Lim SH, Kim SY. Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma. Biochem Biophys Res Commun. 2013; 440:658–63. 10.1016/j.bbrc.2013.09.120 PubMed DOI

Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994; 54:4313–20. PubMed

Yao P, Fox PL. Aminoacyl-tRNA synthetases in medicine and disease. EMBO Mol Med. 2013; 5:332–43. 10.1002/emmm.201100626 PubMed DOI PMC

Drug Resistance in Non-Hodgkin Lymphomas

Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target